Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205

Trial ID or NCT#

NCT01247922

Status

not recruiting iconNOT RECRUITING

Purpose

Participants that were assigned to the oral etoposide treatment arm in protocol OSI-774-205 and either progressed while on study or discontinued due to unacceptable toxicity related to etoposide were allowed to participate in this study to assess the safety profile of single-agent erlotinib in participants with recurrent or refractory pediatric ependymoma.

Official Title

Open-label Phase 2 Study of Single-agent Erlotinib for Patients With Pediatric Ependymoma Previously Treated With Oral Etoposide in Protocol OSI-774-205

Eligibility Criteria

Ages Eligible for Study: 1 Year to 21 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Patients must have been enrolled in OSI-774-205, been randomized to oral etoposide and either progressed while on study or discontinued due to unacceptable toxicity related to etoposide - Performance status: Lansky ≥ 50% for patients ≤ 10 years of age or younger or Karnofsky ≥ 50% for patients greater than 10 years of age - Patients must have recovered from any acute toxicity to any prior anti-cancer treatment - Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age, serum glutamic pyruvic transaminase (SGPT) ALT ≤ 3 x ULN - Serum creatinine based on age OR Creatinine Clearance/Glomerular Filtration Rate (GFR) ≥ 70 mL/min/m2 - Patients must be neurologically stable for at least 7 days before registration - Patients, both males and females, with reproductive potential must agree to practice effective contraceptive measures for the duration of study drug therapy and for at least 90 days after completion of study drug therapy - Patients must be able to take erlotinib orally
Exclusion Criteria:
  1. - Taking strong/moderate CYP3A4 or CYP1A2 inhibitors/inducers ≤ 14 days before registration - Have received any other chemotherapy or immunotherapy to treat ependymoma after discontinuation from OSI-774-205 - Taking proton pump inhibitors ≤ 14 days before registration - Participating in another investigational drug trial while on study - Pregnant or breast-feeding
View All Criteria
Show Less

Investigator(s)

Paul Graham Fisher, MD
Paul Graham Fisher, MD
Neuro-oncologist, Pediatric neurologist
Beirne Family Professor of Pediatric Neuro-Oncology, Professor of Pediatrics and, by courtesy, of Neurosurgery and of Epidemiology and Population Health
Neyssa Marina

Contact us to find out if this trial is right for you.

Contact

Peds Hem/Onc CRAs
650-723-5535

View on ClinicalTrials.gov